As for FLT3 mutations, the potentially risky mutations in CBF-AML, they have been evidenced to negatively affect clinical outcome of CBF-AML [3, 5, 6, 38, 41], and the patients with FLT3 and KIT mutations have a even worse prognosis [6]. The gene discussed is KIT; the disease is acute myeloid leukemia.